Abbott Laboratories (ABT) EV/Assets Ratio: 1.68x
Is Abbott Laboratories’s EV/Assets ratio high or low?
Abbott Laboratories's EV/Assets ratio of 1.68x is 39% below its 5-year average of 2.75x, near the low end of its 5-year range (1.55x–3.55x).
As of Wednesday, June 17, 2026. 32.29% below its 12-month average of 2.48x.
ABT EV/Assets Ratio Chart
ABT Average EV/Assets Ratio Chart
ABT Current vs Average EV/Assets Ratio Chart
ABT EV/Assets Ratio Metrics
EV/ASSETS RATIO
1.68x
EV/ASSETS RATIO AVG TTM
2.48x
EV/ASSETS RATIO AVG 3Y
2.74x
EV/ASSETS RATIO AVG 5Y
2.78x
EV/ASSETS RATIO AVG 10Y
2.44x
EV/ASSETS RATIO AVG 15Y
2.08x
EV/ASSETS RATIO AVG 20Y
1.84x
CURRENT VS TTM AVG
-32.29%
CURRENT VS 3Y AVG
-38.73%
CURRENT VS 5Y AVG
-39.52%
CURRENT VS 10Y AVG
-31.14%
CURRENT VS 15Y AVG
-19.06%
CURRENT VS 20Y AVG
-8.82%
ABT Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | $157.84B | 1.68x | 2.48x | 2.74x | 2.78x |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 3.09x | 3.06x | 2.44x | 2.16x |
| Pfizer Inc. (PFE)vs › | $148.41B | 1.02x | 1.00x | 1.03x | 1.28x |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 7.36x | 8.84x | 9.09x | 8.49x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 1.91x | 2.16x | 2.33x | 2.57x |
| Danaher Corporation (DHR)vs › | $128.72B | 1.69x | 1.98x | 2.16x | 2.26x |
| Amgen Inc. (AMGN)vs › | $187.59B | 2.54x | 2.47x | 2.27x | 2.38x |
| CVS Health Corporation (CVS)vs › | $127.54B | 0.78x | 0.67x | 0.63x | 0.70x |
| Novo Nordisk A/S (NVO)vs › | $193.53B | 2.47x | 3.06x | 23.74x | 33.14x |
| Stryker Corporation (SYK)vs › | $119.06B | 2.86x | 3.26x | 3.42x | 3.27x |
Abbott Laboratories EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Abbott Laboratories (ABT)?
- The EV/Assets ratio for ABT stock is 1.68x.
- Is Abbott Laboratories's EV/Assets ratio high or low?
- Abbott Laboratories's EV/Assets ratio of 1.68x is 39% below its 5-year average of 2.75x, near the low end of its 5-year range (1.55x–3.55x).
- What is the TTM average EV/Assets ratio for Abbott Laboratories (ABT)?
- The TTM average EV/Assets ratio for ABT stock is 2.48x.
- What is the 3Y average EV/Assets ratio for Abbott Laboratories (ABT)?
- The 3Y average EV/Assets ratio for ABT stock is 2.74x.
- What is the 5Y average EV/Assets ratio for Abbott Laboratories (ABT)?
- The 5Y average EV/Assets ratio for ABT stock is 2.78x.
- What is the 10Y average EV/Assets ratio for Abbott Laboratories (ABT)?
- The 10Y average EV/Assets ratio for ABT stock is 2.44x.
- What is the 15Y average EV/Assets ratio for Abbott Laboratories (ABT)?
- The 15Y average EV/Assets ratio for ABT stock is 2.08x.
- What is the 20Y average EV/Assets ratio for Abbott Laboratories (ABT)?
- The 20Y average EV/Assets ratio for ABT stock is 1.84x.
Abbott Laboratories EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-16 | 1.68x |
| 2026-06-15 | 1.65x |
| 2026-06-12 | 1.64x |
| 2026-06-11 | 1.66x |
| 2026-06-10 | 1.66x |
| 2026-06-09 | 1.69x |
| 2026-06-08 | 1.68x |
| 2026-06-05 | 1.69x |
| 2026-06-04 | 1.68x |
| 2026-06-03 | 1.62x |
| 2026-06-02 | 1.62x |
| 2026-06-01 | 1.64x |
| 2026-05-29 | 1.60x |
| 2026-05-28 | 1.61x |
| 2026-05-27 | 1.60x |
| 2026-05-26 | 1.62x |
| 2026-05-22 | 1.63x |
| 2026-05-21 | 1.64x |
| 2026-05-20 | 1.64x |
| 2026-05-19 | 1.65x |
| 2026-05-18 | 1.64x |
| 2026-05-15 | 1.58x |
| 2026-05-14 | 1.59x |
| 2026-05-13 | 1.57x |
| 2026-05-12 | 1.58x |
| 2026-05-11 | 1.55x |
| 2026-05-08 | 1.58x |
| 2026-05-07 | 1.62x |
| 2026-05-06 | 1.61x |
| 2026-05-05 | 1.63x |
| 2026-05-04 | 1.63x |
| 2026-05-01 | 1.66x |
| 2026-04-30 | 1.68x |
| 2026-04-29 | 1.69x |
| 2026-04-28 | 1.97x |
| 2026-04-27 | 1.95x |
| 2026-04-24 | 1.91x |
| 2026-04-23 | 1.94x |
| 2026-04-22 | 1.92x |
| 2026-04-21 | 1.94x |
| 2026-04-20 | 2.01x |
| 2026-04-17 | 2.03x |
| 2026-04-16 | 2.00x |
| 2026-04-15 | 2.12x |
| 2026-04-14 | 2.11x |
| 2026-04-13 | 2.10x |
| 2026-04-10 | 2.10x |
| 2026-04-09 | 2.14x |
| 2026-04-08 | 2.16x |
| 2026-04-07 | 2.13x |
| 2026-04-06 | 2.14x |
| 2026-04-02 | 2.15x |
| 2026-04-01 | 2.14x |
| 2026-03-31 | 2.14x |
| 2026-03-30 | 2.13x |
| 2026-03-27 | 2.17x |
| 2026-03-26 | 2.18x |
| 2026-03-25 | 2.19x |
| 2026-03-24 | 2.17x |
| 2026-03-23 | 2.19x |
| 2026-03-20 | 2.20x |
| 2026-03-19 | 2.24x |
| 2026-03-18 | 2.26x |
| 2026-03-17 | 2.31x |
| 2026-03-16 | 2.29x |
| 2026-03-13 | 2.25x |
| 2026-03-12 | 2.25x |
| 2026-03-11 | 2.30x |
| 2026-03-10 | 2.30x |
| 2026-03-09 | 2.35x |
| 2026-03-06 | 2.28x |
| 2026-03-05 | 2.31x |
| 2026-03-04 | 2.35x |
| 2026-03-03 | 2.36x |
| 2026-03-02 | 2.37x |
| 2026-02-27 | 2.42x |
| 2026-02-26 | 2.42x |
| 2026-02-25 | 2.39x |
| 2026-02-24 | 2.38x |
| 2026-02-23 | 2.40x |
| 2026-02-20 | 2.34x |
| 2026-02-19 | 2.40x |
| 2026-02-18 | 2.42x |
| 2026-02-17 | 2.40x |
| 2026-02-13 | 2.41x |
| 2026-02-12 | 2.38x |
| 2026-02-11 | 2.42x |
| 2026-02-10 | 2.40x |
| 2026-02-09 | 2.37x |
| 2026-02-06 | 2.37x |
| 2026-02-05 | 2.33x |
| 2026-02-04 | 2.31x |
| 2026-02-03 | 2.33x |
| 2026-02-02 | 2.34x |
| 2026-01-30 | 2.34x |
| 2026-01-29 | 2.27x |
| 2026-01-28 | 2.27x |
| 2026-01-27 | 2.31x |
| 2026-01-26 | 2.32x |
| 2026-01-23 | 2.30x |
| 2026-01-22 | 2.32x |
| 2026-01-21 | 2.57x |
| 2026-01-20 | 2.58x |
| 2026-01-16 | 2.59x |
| 2026-01-15 | 2.63x |
| 2026-01-14 | 2.66x |
| 2026-01-13 | 2.65x |
| 2026-01-12 | 2.65x |
| 2026-01-09 | 2.68x |
| 2026-01-08 | 2.69x |
| 2026-01-07 | 2.70x |
| 2026-01-06 | 2.72x |
| 2026-01-05 | 2.69x |
| 2026-01-02 | 2.64x |
| 2025-12-31 | 2.67x |
| 2025-12-30 | 2.68x |
| 2025-12-29 | 2.65x |
| 2025-12-26 | 2.66x |
| 2025-12-24 | 2.66x |
| 2025-12-23 | 2.65x |
| 2025-12-22 | 2.67x |
| 2025-12-19 | 2.67x |
| 2025-12-18 | 2.66x |
| 2025-12-17 | 2.70x |
| 2025-12-16 | 2.70x |
| 2025-12-15 | 2.73x |
| 2025-12-12 | 2.67x |
| 2025-12-11 | 2.63x |
| 2025-12-10 | 2.61x |
| 2025-12-09 | 2.58x |
| 2025-12-08 | 2.60x |
| 2025-12-05 | 2.66x |
| 2025-12-04 | 2.67x |
| 2025-12-03 | 2.67x |
| 2025-12-02 | 2.69x |
| 2025-12-01 | 2.72x |
| 2025-11-28 | 2.74x |
| 2025-11-26 | 2.74x |
| 2025-11-25 | 2.72x |
| 2025-11-24 | 2.71x |
| 2025-11-21 | 2.73x |
| 2025-11-20 | 2.64x |
| 2025-11-19 | 2.69x |
| 2025-11-18 | 2.77x |
| 2025-11-17 | 2.77x |
| 2025-11-14 | 2.78x |
| 2025-11-13 | 2.75x |
| 2025-11-12 | 2.74x |
| 2025-11-11 | 2.70x |
| 2025-11-10 | 2.68x |
| 2025-11-07 | 2.69x |
| 2025-11-06 | 2.66x |
| 2025-11-05 | 2.65x |
| 2025-11-04 | 2.68x |
| 2025-11-03 | 2.64x |
| 2025-10-31 | 2.63x |
| 2025-10-30 | 2.65x |
| 2025-10-29 | 2.65x |
| 2025-10-28 | 2.72x |
| 2025-10-27 | 2.73x |
| 2025-10-24 | 2.72x |
| 2025-10-23 | 2.71x |
| 2025-10-22 | 2.74x |
| 2025-10-21 | 2.74x |
| 2025-10-20 | 2.78x |
| 2025-10-17 | 2.76x |
| 2025-10-16 | 2.74x |
| 2025-10-15 | 2.78x |
| 2025-10-14 | 2.86x |
| 2025-10-13 | 2.82x |
| 2025-10-10 | 2.84x |
| 2025-10-09 | 2.86x |
| 2025-10-08 | 2.88x |
| 2025-10-07 | 2.85x |
| 2025-10-06 | 2.87x |
| 2025-10-03 | 2.88x |
| 2025-10-02 | 2.85x |
| 2025-10-01 | 2.86x |
| 2025-09-30 | 2.87x |
| 2025-09-29 | 2.85x |
| 2025-09-26 | 2.86x |
| 2025-09-25 | 2.86x |
| 2025-09-24 | 2.87x |
| 2025-09-23 | 2.91x |
| 2025-09-22 | 2.93x |
| 2025-09-19 | 2.91x |
| 2025-09-18 | 2.88x |
| 2025-09-17 | 2.87x |
| 2025-09-16 | 2.84x |
| 2025-09-15 | 2.81x |
| 2025-09-12 | 2.86x |
| 2025-09-11 | 2.84x |
| 2025-09-10 | 2.77x |
| 2025-09-09 | 2.83x |
| 2025-09-08 | 2.83x |
| 2025-09-05 | 2.85x |
| 2025-09-04 | 2.85x |
| 2025-09-03 | 2.83x |
| 2025-09-02 | 2.82x |
| 2025-08-29 | 2.84x |
| 2025-08-28 | 2.82x |
| 2025-08-27 | 2.82x |
| 2025-08-26 | 2.82x |
| 2025-08-25 | 2.83x |
| 2025-08-22 | 2.84x |
| 2025-08-21 | 2.83x |
| 2025-08-20 | 2.84x |
| 2025-08-19 | 2.81x |
| 2025-08-18 | 2.79x |
| 2025-08-15 | 2.82x |
| 2025-08-14 | 2.77x |
| 2025-08-13 | 2.77x |
| 2025-08-12 | 2.81x |
| 2025-08-11 | 2.82x |
| 2025-08-08 | 2.88x |
| 2025-08-07 | 2.83x |
| 2025-08-06 | 2.81x |
| 2025-08-05 | 2.80x |
| 2025-08-04 | 2.79x |
| 2025-08-01 | 2.73x |
| 2025-07-31 | 2.71x |
| 2025-07-30 | 2.76x |
| 2025-07-29 | 2.83x |
| 2025-07-28 | 2.79x |
| 2025-07-25 | 2.80x |
| 2025-07-24 | 2.78x |
| 2025-07-23 | 2.78x |
| 2025-07-22 | 2.78x |
| 2025-07-21 | 2.75x |
| 2025-07-18 | 2.74x |
| 2025-07-17 | 2.67x |
| 2025-07-16 | 2.91x |
| 2025-07-15 | 2.90x |
| 2025-07-14 | 2.91x |
| 2025-07-11 | 2.91x |
| 2025-07-10 | 2.95x |
| 2025-07-09 | 2.94x |
| 2025-07-08 | 2.94x |
| 2025-07-07 | 2.95x |
| 2025-07-03 | 2.97x |
| 2025-07-02 | 2.96x |
| 2025-07-01 | 3.01x |
| 2025-06-30 | 3.00x |
| 2025-06-27 | 2.97x |
| 2025-06-26 | 2.95x |
| 2025-06-25 | 3.03x |
| 2025-06-24 | 3.04x |
| 2025-06-23 | 2.94x |
| 2025-06-20 | 2.94x |
| 2025-06-18 | 2.92x |
| 2025-06-17 | 2.92x |
| 2025-06-16 | 2.96x |
| 2025-06-13 | 2.99x |
| 2025-06-12 | 3.01x |
| 2025-06-11 | 2.98x |
| 2025-06-10 | 2.96x |
| 2025-06-09 | 2.94x |
| 2025-06-06 | 2.95x |
| 2025-06-05 | 2.96x |
| 2025-06-04 | 2.93x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford